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Abstract
Screening to detect colorectal cancer (CRC) in an early or premalignant state is an effective method to reduce CRC
mortality rates. Current stool-based screening tests, e.g. fecal immunochemical test (FIT), have a suboptimal sen-
sitivity for colorectal adenomas and difficulty distinguishing adenomas at high risk of progressing to cancer from
those at lower risk. We aimed to identify stool protein biomarker panels that can be used for the early detection
of high-risk adenomas and CRC. Proteomics data (LC–MS/MS) were collected on stool samples from adenoma
(n= 71) and CRC patients (n= 81) as well as controls (n= 129). Colorectal adenoma tissue samples were charac-
terized by low-coverage whole-genome sequencing to determine their risk of progression based on specific DNA
copy number changes. Proteomics data were used for logistic regression modeling to establish protein biomarker
panels. In total, 15 of the adenomas (15.8%) were defined as high risk of progressing to cancer. A protein panel,
consisting of haptoglobin (Hp), LAMP1, SYNE2, and ANXA6, was identified for the detection of high-risk adenomas
(sensitivity of 53% at specificity of 95%). Two panels, one consisting of Hp and LRG1 and one of Hp, LRG1, RBP4,
and FN1, were identified for high-risk adenomas and CRCs detection (sensitivity of 66% and 62%, respectively,
at specificity of 95%). Validation of Hp as a biomarker for high-risk adenomas and CRCs was performed using an
antibody-based assay in FIT samples from a subset of individuals from the discovery series (n= 158) and an inde-
pendent validation series (n= 795). Hp protein was significantly more abundant in high-risk adenoma FIT samples
compared to controls in the discovery (p= 0.036) and the validation series (p= 9e-5). We conclude that Hp,
LAMP1, SYNE2, LRG1, RBP4, FN1, and ANXA6 may be of value as stool biomarkers for early detection of high-risk
adenomas and CRCs.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Colorectal cancer (CRC) remains a major health care
problem, representing 6.1% of all cancers worldwide
[1]. Early detection through population screening is
an efficient method to reduce the burden of CRC,
and screening programs have been implemented in
many countries [2]. Screening programs aim to detect
CRC at a curable stage or when it is still at a pre-
cursor non-malignant stage (i.e. colorectal adenoma),
and have been proven to reduce CRC mortality rates
[3–5]. Most population screening programs use a
fecal immunochemical test (FIT) as a triage test to
colonoscopy [2]. In this setting, all participants with
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
Stool protein biomarkers for high-risk adenomas 289
a positive FIT are referred for colonoscopy, during
which adenomas and early cancers can be diagnosed
and removed.
The reported sensitivity of FIT depends on the study
characteristics but is overall high for CRC (67–86%)
and relatively low for colorectal adenomas (29–35%),
leaving room for improvement [6–8]. It has been sug-
gested that an increase in sensitivity for colorectal
adenomas is the best approach to make CRC screening
more cost-effective and efficient [9–11]. However,
detecting all adenomas during screening is not the aim,
as only approximately 5% of all adenomas are expected
to develop into cancer [12]. Advanced adenomas,
defined as adenomas with a size of ≥ 10mm, a villous
component of ≥ 25%, and/or high-grade dysplasia, are
currently regarded as an intermediate endpoint for CRC
in screening programs, since advanced adenomas are
considered to carry a higher risk of developing into
CRC than non-advanced adenomas [13–15]. Based on
the fact that advanced adenomas are far more prevalent
than CRC, not all advanced adenomas are expected to
progress [12].Therefore, it is important to develop new
screening tests directed at the identification of those
lesions with the highest risk of progression.
Cancer is caused by DNA alterations, includ-
ing specific changes in DNA copy numbers. Gains
of chromosomal arms 8q, 13q, and 20q, and
losses of 8p, 15q, 17p, and 18q have been associ-
ated with adenoma-to-carcinoma progression (i.e.
cancer-associated events or CAEs) [16,17]. Adeno-
mas carrying two or more CAEs are considered at
high risk of progression, i.e. high-risk adenomas [17].
Approximately 23–36% of advanced adenomas and
1.7–4.8% of non-advanced adenomas were reported
to be high-risk adenomas [18]. Based on the incidence
of CRC, the molecularly defined high-risk adenoma
phenotype may better reflect the true progression risk
than the advanced adenoma phenotype.
We have previously reported on stool protein
biomarkers, which increased sensitivity compared
with hemoglobin for detection of CRC and advanced
adenomas [19]. In contrast to the previous study
where the focus was on advanced adenomas, here a
molecularly-defined intermediate endpoint was applied
for biomarker discovery. In this study, we set out to
further explore the same proteomics dataset for iden-
tification of protein biomarkers that are specifically
suited for the detection of molecularly defined high-risk
adenomas.
Materials and methods
The design of the study is presented in Figure 1.
Samples
Informed consent was obtained from all subjects who
provided stool and FIT samples. Collection, storage, and
use of patient-derived tissue and data were performed in
compliance with the ‘Code for Proper Secondary Use
of Human Tissue in The Netherlands’ by the Dutch
Federation of Biomedical Scientific Societies [20].
Stool, tissue, and FIT samples of the discovery series
For discovery, whole stool samples from 293 individ-
uals diagnosed with CRC (n= 81), advanced adenoma
(n= 40) or non-advanced adenoma (n= 43) as most
advanced lesion, and individuals without colorectal
neoplasia (n= 129), further referred to as ‘controls’,
were collected from a referral population that underwent
colonoscopy at multiple centers in The Netherlands and
Germany between 2005 and 2012. Sample description
and processing have been previously described [19]. In
total for 71 adenoma patients, formalin-fixed, paraffin
embedded (FFPE) tissue samples were available and
requested from the pathology archive of the Amsterdam
UMC, location VUmc, The Netherlands. In total, 95
tissue samples were retrieved, as some individuals
carried multiple adenomas.
From a subset of the individuals from the dis-
covery series (n= 162), FIT samples (OC-sensor;
Eiken Chemical, Tokyo, Japan) were obtained prior to
colonoscopy. These included patients diagnosed with
CRC (n= 17), high-risk adenoma (n= 10) or low-risk
adenomas (n= 39) asmost advanced lesion, and controls
(n= 96).
FIT samples of the validation series
Between June 2009 and July 2010, in a population-based
screening study [COlonoscopy or COlonography
for Screening (COCOS) trial] run in The Nether-
lands, asymptomatic individuals were invited for
primary colonoscopy screening [21,22]. Screening
participants allocated to the colonoscopy arm of the
COCOS trial were invited to collect a FIT sample
(OC-sensor; Eiken Chemical) prior to their screening
colonoscopy. FIT samples from 795 individuals diag-
nosed with CRC (n= 8), high-risk adenomas (n= 19)
or low-risk adenomas (n= 52) as most advanced lesion,
or without colorectal neoplasia (n= 716) were used for
validation.
DNA copy number analysis using low-coverage
whole-genome sequencing
DNA was isolated from FFPE tissues with a
column-based method (QIamp DNA microkit; Qia-
gen, Hilden, Germany) as described before [18,23].
DNA copy number analysis (supplementary material,
Supplementary materials and methods) and status for
adenomas of the discovery and the validation series
have been reported previously [18]; data are avail-
able in the European Genome and Phenome Archive
(EGAS0000100295). If two or more CAEs were
present, an adenoma was classified as high-risk ade-
noma [17,18]. Individuals with at least one high-risk
adenoma were defined as high risk.
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Figure 1. Overview of the design of this study. The discovery series consisted of control, colorectal adenoma, and colorectal cancer (CRC)
samples. FFPE tissue blocks were obtained from 71 adenoma patients and low-coverage whole-genome sequencing was performed to
identify DNA copy number aberrations. Fifteen high-risk adenomas were identified according to their DNA copy number profiles. Whole
stool samples of individuals from the discovery series were used for mass spectrometry proteomics analysis. Proteins identified were used
for biomarker panel identification for high-risk adenomas and high-risk adenomas together with CRCs. An immunoassay was applied on
158 FIT samples from the discovery series and 795 FIT samples from the validation series for biomarker validation, to evaluate quantitative
difference of Hp between controls, low-risk adenomas, high-risk adenomas, and CRCs.
LC–MS/MS data analysis
The tandem mass spectrometry (LC–MS/MS) data on
the stool samples of the 293 individuals were read-
ily available and described previously (PRIDE ID:
PXD007767) [19]. Protein identification was performed
with MaxQuant [24] as described previously [19]
with some adaptations (see supplementary material,
Supplementary materials and methods).
Protein biomarker panel identification with logistic
regression
An overview of the data analysis approach is presented
in supplementary material, Figure S1. Proteins with
higher abundance in cases (high-risk adenomas or
high-risk adenomas and CRCs) compared with controls
constituted input for selecting biomarker panels. Logis-
tic regression analysis with Lasso regularization was
used to identify biomarker panels consisting of two,
three or four proteins that best distinguish cases from
controls. A leave-one-out cross-validation procedure
was applied to evaluate the performance of the model.
Cross-validated logistic predictions were obtained.
Receiver operating characteristic (ROC) analysis was
used to evaluate the performance of protein panels to
discriminate cases from controls by calculating the
partial area under the curve (pAUC) between specificity
of 95% and 100%, and by calculating sensitivity at 95%
specificity. The pAUC was compared with the pAUC of
haemoglobin (HBA1). P values were obtained with the
stratified bootstrap resampling of case/control labels of
the individuals with 2000 permutations [25].
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Haptoglobin (Hp) quantification in FIT samples
FIT samples from both the discovery and the validation
series were analyzed with an antibody-based assay
(Figure 1). From the 162 FIT samples in the discovery
series, four were excluded due to technical reasons
(controls n= 3, CRC n= 1), leaving 158 samples for
Hp quantification. Immunoassays for Hp employing a
sandwich immunoassay format and electrochemilumi-
nescence (ECL) detection were carried out on commer-
cial instrumentation and multi-well plate consumables
from Meso Scale Diagnostics, LLC (MSD; Rockville,
MD, USA); more details may be found in supplemen-
tary material, Supplementary materials and methods
[26]. All samples were analyzed in duplicate and final
analyses were performed on mean concentrations.
FIT values – correlation analysis
In the discovery series, hemoglobin (HBA1 and HBB)
and haptoglobin (Hp) protein abundance as determined
bymass spectrometry were compared with FIT values in
the same samples. Missing values were excluded from
the analysis. Spearman correlation analysis was per-
formed on normalized spectral counts of HBA1, HBB,
Hp and FIT values, correlation coefficients (rho) and P
values were obtained.
Results
Characterization of cancer-associated events
in colorectal adenomas
In total, 95 adenomas from 71 adenoma patients from
the discovery series were available for CAE identifica-
tion as was described before (supplementary material,
Figure S2) [18]. A complete overview of the frequen-
cies and the associations with adenoma histologic fea-
tures may be found in supplementary material, Table S1.
Two CAEs or more, indicating a higher risk of pro-
gression, were identified in 15.8% of all adenomas
(n= 15; further referred to as high-risk adenomas), in
36.4% (12/33) of advanced adenomas, and in 4.8%
(3/62) of non-advanced adenomas (supplementarymate-
rial, Table S1 and Figure S2).
Protein profiling and selection of candidate
biomarkers
In the discovery series, proteomics profiling of all stool
samples revealed 792 protein groups (FDR≤ 0.01;
supplementary material, Table S2). Correlation analysis
was performed between FIT values obtained from a
subsample of the same bowel movement and normalized
spectral counts for hemoglobin, in particular for HBA1
and HBB separately. Significant positive correlations
were identified for both HBA1 (rho= 0.46, p< 0.001)
and HBB (rho= 0.43, p< 0.001; supplementary mate-
rial, Figure S3). Dimensionality reduction performed
on the protein expression profiles distinguished stool
samples from CRC patients from those with adeno-
mas or controls (Figure 2A). To identify proteins that
discriminate high-risk adenomas from controls, we
performed differential protein expression analysis. This
yielded 31 proteins more abundant in high-risk ade-
noma stool samples (log2 fold-change> 0 and p≤ 0.1;
Figure 2B). Additionally, we performed differential
protein expression analysis to identify proteins dif-
ferentiating all screen-relevant lesions, i.e. CRCs and
high-risk adenomas, from controls. Application of the
same threshold revealed 125 protein groups to be more
highly expressed in high-risk adenomas and CRCs. For
further analysis, a more stringent threshold was applied
(i.e. log2 fold-change≥ 2, adjusted p≤ 0.05) and
revealed 61 proteins more abundant in screen-relevant
lesions compared with controls (Figure 2C). Significant
overlap was identified between differentially expressed
proteins from both analyses (p = 1.47e−4, hypergeomet-
ric test) with 13 proteins overlapping: CP, Hp, A2M, C3,
C5, APCS, TF, ANXA6, C4B, C6, STOM, SERPINA4,
and ITIH4.
Biomarker panel selection for high-risk adenomas
The proteomics dataset was further investigated to find
biomarker panels of complementary proteins that would
perform better than hemoglobin in distinguishing indi-
viduals with high-risk adenomas from controls and a
combination of high-risk adenomas and CRCs from con-
trols. Panels of two, three or four proteins were exam-
ined. To evaluate the diagnostic performance of each
biomarker panel in the context of population screening,
we compared its performance to hemoglobin, which is
the protein currently used in CRC screening by means of
FIT. Since FIT values were not available for the whole
dataset, the performance of the biomarker panel was
compared with HBA1 quantified by LC–MS/MS as a
substitute (for comparison to FIT, see supplementary
material, Figure S4). The analysis was done on a par-
tial AUC (pAUC) at the specificity level between 95%
and 100% and sensitivity was evaluated at 95% speci-
ficity, since high specificity is pivotal for the success of
a population screening program.
First, we applied logistic regression with Lasso reg-
ularization on the 31 up-regulated proteins in high-risk
adenomas to identify a biomarker panel (see supplemen-
tary material, Figure S1 for the data analysis overview).
In the resulting regression model, Hp, LAMP1, SYNE2,
and ANXA6 were selected, while the models for three
or two proteins were not built, as due to the Lasso
regularization the coefficients for LAMP1, SYNE2, and
ANXA6 shrunk to zero at the same time, meaning that
the three proteins were excluded from the regression
model at once. Then the performance of the model was
evaluated using leave-one-out cross-validation and an
ROC analysis was used to compare to the performance
of hemoglobin. In the cross-validation procedure, only
models based on four proteins were included (Figure 3).
Despite the fact that the pAUC of the biomarker
panel (pAUC= 60.2%) was higher than that for HBA1
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Figure 2. Proteomics profiling of human stool samples. (A) Multidimensional scaling of protein expression profiles of stool samples
derived from controls (n= 129), individuals with low-risk adenomas (n= 56), high-risk adenomas (n= 15), and cancers (n= 79). (B)
Hierarchical clustering of protein profiles of stool samples derived from high-risk adenomas and controls based on 31 proteins expressed
more highly in high-risk adenomas compared with controls. (C) Hierarchical clustering of protein profiles of stool samples derived from
CRCs, high-risk adenomas, and controls based on 61 proteins expressed more highly in CRCs and high-risk adenomas compared with
controls.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2020; 250: 288–298
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Figure 3. Biomarker panels from logistic regression analysis to identify high-risk adenomas and CRCs. (A) ROC curve of the regression
model using the four-biomarker panel (Hp, LAMP1, SYNE2, and ANXA6) to distinguish between stool samples from individuals with
high-risk adenomas (n= 15) and controls (n= 129). ROC curve was obtained from logistic regression predictions from the leave-one-out
cross-validation analysis. Partial area under the curve (pAUC) was calculated for specificity of 95–100% and compared with pAUC of
hemoglobin to obtain the P value. (B) Frequency plot of biomarkers occurring in the regression models built during the cross-validation
analysis to distinguish between the high-risk adenomas and controls. Four proteins were clearly selected more frequently by the Lasso
regularization in the cross-validation analysis.
(pAUC= 54.5%), the difference was not significant.
At the specificity level of 95%, the biomarker panel
could identify 8 out of 15 high-risk adenomas (sensi-
tivity= 54%, CI= [27, 79%]), which was more than
hemoglobin (sensitivity= 13%, CI= [2, 40%], see
Table 1A). The markers most frequently selected in the
cross-validation procedure were Hp, LAMP1, SYNE2,
and ANXA6, with a frequency of over 90%, indicating
that these proteins have the most discriminative roles in
the regression models (Figure 3B).
The model was also applied to low-risk adenomas.
Here, five (9%, CI= [3, 20%]) low-risk adenomas were
classified as cases and 51 (91%) as controls, indicating
that this biomarker panel has a high specificity for the
identification of high-risk adenomas (see supplementary
material, Table S3).
Biomarker panel selection for high-risk adenomas
and CRCs combined
Next, we performed the same analysis for the 61
up-regulated proteins in stool samples derived from indi-
viduals with high-risk adenomas and CRCs. The model
with four protein biomarkers consisted of Hp, LRG1,
RBP4, and FN1; the model with three features was not
built, as due to Lasso regularization the coefficients of
FN1 and RBP4 shrunk to zero at the same time; and the
model of two proteins consisted of Hp and LRG1. In the
cross-validation procedure, the models of four and two
proteins were evaluated (Figure 4). The cross-validated
pAUCs of the four- (pAUC= 70.4%) and two-protein
(pAUC= 71.1%) models significantly outperformed
hemoglobin (pAUC HBA1= 62.7%, both p= 0.007;
Figure 4A,C). At the specificity level of 95%, the four-
and two-biomarker panels could identify 58 and 62
out of 94 cases, respectively (sensitivity= 62 and 66%,
CI= [51, 72%] and [55, 75%]), which was more than
HBA1 (sensitivity= 40%, CI= [30, 51%]; Table 1B).
The most frequent proteins included in the four-protein
regression models in the cross-validation procedure
were Hp, LRG1, RBP4, and FN1, with frequencies of
over 90%, confirming their predictive characteristics
and the stability of the model (Figure 4B). The model
with two proteins always consisted of Hp and LRG1 in
the cross-validation procedure, indicating their strongest
predictive characteristics (Figure 4D).
The four- and two-protein models were also tested for
identification of low-risk adenomas. The four-protein
panel classified six (11%, CI= [4, 22%]) out of 56
low-risk adenomas as cases and 50 (89%) as con-
trols, while the two-protein panel classified seven (13%,
CI= [5, 24%]) low-risk adenomas as cases and 49 (87%)
as controls (supplementary material, Table S3).
When focusing on the overlap of up-regulated pro-
teins in both comparisons and the biomarker panels
selected by Lasso regularization, Hp was the only pro-
tein present in all panels. This suggests that Hp might
be a crucial component when distinguishing between
high-risk adenomas and CRCs from controls.
Validation of Hp expression by immunoassay in FIT
samples
As Hp forms a complex with hemoglobin, we explored
if the protein abundance as measured by mass spectrom-
etry was correlated to FIT and/or hemoglobin (supple-
mentary material, Figure S3). As expected, we observed
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Table 1. Confusion matrix for the cross-validated performance of
the models of biomarker panels. Performance of the biomarker
panel regression models was evaluated at 95% specificity and
compared with hemoglobin. (A) High-risk adenomas versus








Hp, LAMP1, SYNE2, ANXA6

















Hp, LRG1, RBP4, FN1














a strong correlation to HBA1 and HBB and a some-
what weaker correlation to FIT (correlation coeffi-
cient 0.77, 0.67, and 0.55, respectively; p < 0.001 for
all comparisons). In line with this, Hp as a single
marker did not outperform FIT (supplementary material,
Figure S5).
Nevertheless, as in the regression models Hp was
consistently selected in all three marker panels, we
further explored the Hp levels in two FIT cohorts. Using
an immunoassay, Hp quantification was successfully
performed in FIT samples of a subset of individu-
als from the discovery series (n= 158; 16 CRCs, 10
high-risk adenomas, 39 low-risk adenomas, and 93
controls). A significantly higher concentration of Hp
was identified in the high-risk adenoma samples com-
pared with the controls (fold-change= 1.9, p= 0.036;
Figure 5A). Additionally, an independent validation
series was used (Figure 5B), which consisted of 716
controls, 52 low-risk adenomas, 19 high-risk adeno-
mas, and 8 CRCs. Here, a higher abundance of Hp
in high-risk adenomas (fold-change =15.9, p= 9e−5)
and CRCs (fold-change= 42.6, p= 9.7e−5) compared
with controls was confirmed. This confirms our find-
ings by mass spectrometry and suggests that Hp can
be applied as a biomarker for high-risk adenomas
and CRCs.
Discussion
It is well known that not all colorectal adenomas will
progress to CRC. This underlines the importance of
developing screening tests for the detection of specifi-
cally those adenomas that are at high risk of progressing
to malignancy [27]. The widely used FIT is not optimal
for detecting such adenomas, and therefore additional
biomarkers could aid in improving sensitivity for early
detection of CRC. Proteins are an attractive category of
molecules to be used as biomarkers for application in
stool-based CRC screening, as they can be measured in
small sample volumes with simple economic assays like
FIT [28]. In the present study, we aimed to identify com-
binations of specific stool-based protein biomarkers that
outperform hemoglobin in the detection of molecularly
defined high-risk adenomas and CRCs. Based on their
DNA copy number profiles, adenomas were classified
into lesions at low or high risk of progressing to cancer
[16–18]. High-risk adenomas comprised 15.8% of all
adenomas and 36.4% of the advanced adenomas. Using
mass spectrometry proteomics on stool samples and
regression modeling, we selected marker panels consist-
ing of up to four proteins that distinguish screen-relevant
lesions, i.e. high-risk adenomas and CRCs, from con-
trols. We identified a biomarker panel of Hp, LAMP1,
SYNE2, and ANXA6 for identification of high-risk ade-
nomas and two biomarker panels – Hp and LRG1, as
well as Hp, LRG1, RBP4, and FN1 – for identifica-
tion of high-risk adenomas and CRCs that outperformed
hemoglobin. Since Hp was the single protein present in
all three biomarker panels, it was selected for further val-
idation. To test its applicability in a screening setting, we
used antibody-based assays on FIT samples for the val-
idation experiments. The higher concentration of Hp in
high-risk adenomas and CRCs compared with controls
was confirmed using an immunoassay in FIT samples of
both the discovery series and a validation series.
Using mass spectrometry analysis of stool samples,
we previously established protein panels that showed
a higher sensitivity for advanced adenoma and CRC
samples compared with hemoglobin [19]. In the present
study, we performed subsequent statistical analyses to
select alternative candidate biomarkers, including the
most promising protein combinations that may improve
the current stool-based CRC population screening in
the detection of high-risk adenomas and CRCs. Statisti-
cal analysis of discovery mass spectrometry proteomics
datasets on complex samples like stool are challenging
due to missing data. Therefore, two feature selection
methods were used to select the best biomarker panels
for identification of cases versus controls, accounting
for the complexity of our dataset: the beta-binomial test
[29] and Lasso regularization in the regression model-
ing [30]. The beta-binomial test was used for detection
of proteins more highly expressed in the cases than in
the controls, while logistic regression with Lasso regu-
larization was applied to select for the best combination
of these more highly expressed proteins to distinguish
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Figure 4. Biomarker panels from logistic regression analysis to identify high-risk adenomas and CRCs. (A) ROC curve of the model based on
the panel of four biomarkers (Hp, LRG1, RBP4, and FN1) for high-risk adenomas and CRCs (n= 94) compared with controls (n= 129). ROC
curve was obtained from logistic regression predictions from the leave-one-out cross-validation analysis. (B) Frequency plot of biomarkers
occurring in the regression models built during the cross-validation analysis to discriminate high-risk adenomas and CRCs from controls
based on four proteins. Four proteins were clearly selected more frequently by the Lasso regularization in the cross-validation analysis.
(C) ROC curve of the model based on the panel of two biomarkers (Hp and LRG1) for high-risk adenomas and CRCs (n= 94) compared
with controls (n= 129). ROC curve was obtained from logistic regression predictions from the leave-one-out cross-validation analysis.
(D) Frequency plot of biomarkers occurring in the regression models built during the cross-validation analysis to discriminate high-risk
adenomas and CRCs from controls based on two proteins. The same two proteins were consistently selected in the cross-validation analysis.
cases from the controls. Lasso regularization shrinks
coefficients of less importance or correlating features to
zero, therefore achieving a sparser solution, i.e. a smaller
number of features in the final regression model. This
method not only avoids overfitting but also performs fea-
ture selection of the best performing model.
A limitation of this study was the small number
of molecularly defined high-risk adenoma patients
(n= 15), which affected the performance of the model
built on only high-risk adenomas as cases. Based on
our previous work, it was anticipated that only a limited
number of even the morphologically defined advanced
adenomas would carry two or more CAEs [18]. How-
ever, the most relevant screening targets are CRCs as
well as adenomas considered at high risk of progres-
sion. In line with this approach, combining CRCs and
molecularly defined high-risk adenomas increased the
size of the set of cases, and improved the performance
of the models. Moreover, in the discovery series, FIT
results were not available for all samples (162 out of
277 samples), which limited the possibilities of direct
comparison of the marker panels with FIT performance,
especially for the high-risk adenomas (n= 10 with FIT
available).
The marker panels in the discovery phase con-
sistently contained haptoglobin (Hp), which as the
hemoglobin–haptoglobin complex has been previously
investigated as a biomarker for CRC [31]. The Hp–Hb
complex has been suggested to render a more stable
biomarker than Hb or Hp alone, and could therefore
increase sensitivity for the more proximal lesions in
the bowel [32]. This, however, was not confirmed in the
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Figure 5. Validation of Hp protein expression with the use of an immunoassay. (A) The discovery series. (B) The validation series.
current study (data not shown). It has been described
that the sensitivity for CRC does not increase with
the detection of an Hp–Hb complex compared with
hemoglobin alone, but the sensitivity for adenomas does
[33]. In this study, the sensitivity of the complex versus
the single proteins could not be assessed. Nevertheless,
using an antibody-based assay, a higher abundance
of Hp was confirmed in FIT samples of patients with
high-risk adenomas and CRCs in the discovery series
and in a much larger independent validation series.
These findings underline the importance of Hp as a
biomarker for screen-relevant lesions and hold promise
for future application of Hp in CRC screening. Mean-
while, hemoglobin (HBA1, HBB or HBD) was not
significantly differential between high-risk adenomas
and controls, and subsequently it was not selected in
any of the biomarker panels, which is in line with the
limited sensitivity of FIT for adenomas. Although one
would expect that Hp is a marker of blood in the stool
and therefore should not have complementary value to
hemoglobin, our data suggest that Hp is of added value
for the detection of high-risk adenomas. A possible
explanation may be that the Hp protein detected in stool
is not only derived from blood but may also be derived
from the CRC or high-risk adenoma tissues. In line
with this, Hp has been described to be expressed by
colorectal cancer cells: both cell lines and within the
tumor, where its expression was associated with the
stage of progression [34].
Next to Hp, LAMP1, SYNE2, and ANXA6 were
selected in the analysis for high-risk adenomas, and
also LRG1, RBP4, and FN1 for the high-risk adenomas
and CRCs. LAMP1 is a lysosome-associated mem-
brane protein which has been implicated in several
tumor-promoting activities such as promotion of metas-
tasis, drug resistance, and cancer cell survival [35]. The
gene coding for LAMP1 is located on chromosome
13q, gain of which is one of the seven CAEs used for
classifying adenomas as high-risk. SYNE2 (or nesprin
2) is a nuclear envelope protein that is involved in the
regulation of nuclear trafficking; even though its role
in cancer is yet to be established, there are indications
that its presence is pivotal in the DNA damage response
[36]. Since high-risk adenomas are characterized by
chromosomal gains and losses, the up-regulation of
SYNE2 might be linked to these DNA aberrations.
ANXA6 is present at the cell membrane and in the
endosomal compartments, where it functions as a multi-
functional scaffolding protein. In that position, ANXA6
can contribute to many different processes including
cancer cell migration and invasion [37]. RBP4 has been
linked to insulin resistance and has been shown to be
present in the serum of breast cancer patients [38]; it was
previously described as a potential marker for colorectal
advanced adenomas in stool [19]. FN1 is an extracellu-
lar matrix protein that is involved in cell adhesion and
migration processes; it has been shown to be present
in the serum of patients with hepatocellular carcinoma
and has been suggested as a biomarker for this disease
[39]. Finally, LRG1 has been reported to be highly
up-regulated in CRC, both at the mRNA and at the pro-
tein level [40,41]. An evident role in tumor development
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has been established for LRG1, as it stimulates prolif-
eration and inhibition of apoptosis through regulating
RUNX1 expression [40,42]. In addition, the protein is
secreted and may therefore end up in blood or stool.
Indeed, increased protein levels of LRG1 in plasma have
been reported for colorectal cancer and colon adenoma
patients [40,43,44]. Altogether, for the majority of these
biomarker proteins their potential involvement in tumor
biology has been demonstrated. Further investigation
is needed to evaluate the diagnostic potential of these
protein biomarkers in a CRC screening setting.
The present study is unique because a
molecularly-defined intermediate endpoint was used for
biomarker discovery, by applying chromosomal copy
number alterations highly associated with colorectal
adenoma-to-carcinoma progression. This is in contrast
to the morphological features traditionally used to
define the advanced adenoma intermediate endpoint.
Our study resulted in the identification of novel protein
biomarker panels with higher sensitivities for high-risk
adenomas and CRCs than HBA1, which have plausible
roles in colorectal carcinogenesis. FIT has a low sensi-
tivity for colon adenomas; by increasing the sensitivity
for high-risk adenomas, we can raise the detection rates
for these lesions. Therefore, these biomarkers have
the potential to improve current FIT-based screening
strategies.
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